Pidilizumab is under clinical development by Pfizer and currently in Phase II for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase II drugs for Multiple Myeloma (Kahler Disease) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pidilizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pidilizumab overview
Pidilizumab (CT-011) is under development for the treatment of refractory and relapsed multiple myeloma. CT-011 is an intravenously administered humanized monoclonal antibody (mAb) as an infusion. It acts by targeting programmed cell death protein 1 (PD1).
See Also:
It was also under development for hepatocellular carcinoma, acute myelocytic leukemia (AML), hepatitis C, metastatic colorectal cancer, follicular lymphoma, renal cell carcinoma, metastatic melanoma, diffuse large B-cell lymphoma, diffuse intrinsic pontine glioma and pancreatic cancer.
For a complete picture of Pidilizumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
